tirzepatide vs semaglutide risks vs. Semaglutide: Key Differences & Benefits Lower cardiovascular event risk with

A recent population-based study involving 1,961 patients with newly diagnosed glaucoma revealed that GLP-1RA use was significantly associated with a reduced risk of developing the disease

They may also provide cardiovascular and kidney benefits in the right patient

That is, until Ozempic (active ingredient: semaglutide)a GLP-1 medication originally conceived to treat Type 2 diabetesbegan being marketed for weight loss alongside other injectable drugs, including Wegovy (the generic brand my then-insurance company agreed to fill) and Mounjaro (active ingredient: tirzepatide)

Rybelsus FDA-Approval and Its Black Box Warning On September 20, 2019, the FDA approved Rybelsus as the first oral GLP-1 treatment for type 2 diabetes